 |
Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends
Apr 23, 2013
|
9.5 KB |
|
| |
PISCATAWAY, NJ -- (Marketwired) -- 04/23/13 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it has concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the Company, and that its Board of Directors has approved a $1.60 special dividend per share and intends to distribute...
|
|
Enzon Reports Fourth Quarter and Full Year 2012 Results
Mar 18, 2013
|
18.6 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 03/18/13 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth quarter and full year 2012. For the three months ended December 31, 2012, Enzon reported a loss from continuing operations of $5.2 million, or $0.11 per diluted share, compared to a loss from continuing o...
|
|
Enzon to Review Asset Sales, Sale of the Company
Dec 17, 2012
|
8.3 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 12/17/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that its Board of Directors has retained Lazard to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets, or a sale of the Company. Based on clinical data on the androgen receptor program, E...
|
|
Enzon Announces Special Dividend
Nov 29, 2012
|
7.7 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 11/29/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that its Board of Directors has authorized a special dividend of $2.00 per common share, payable on December 21, 2012 to shareholders of record as of December 10, 2012.
Alex Denner, Chairman of the Board, commented: "In additi...
|
|
Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China
Nov 8, 2012
|
10.4 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 11/08/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced two oral presentations at the 2nd Annual Symposium of Drug Delivery Systems-2012, which is being held November 8-10 in Nanjing, China. The presentations will highlight Enzon's Customized Linker Technology®, the conjugation of a molecule...
|
|
Enzon Reports Third Quarter 2012 Results
Oct 31, 2012
|
15.8 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 10/31/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2012. Enzon reported net income of $4.2 million, or $0.08 diluted earnings per share, for the third quarter of 2012, as compared to a net loss of $9.1 million, or $0.19 diluted loss per share, f...
|
|
Enzon to Present at 2012 World Congress and Expo on Biowaivers and Biosimilars
Sep 11, 2012
|
9.7 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 09/11/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it will present at the 2012 World Congress and Expo on Biowaivers and Biosimilars, which is being held September 10-12 in San Antonio, TX. The Company was selected to give a presentation and overview of PEGylation, its Customized Linker...
|
|
Enzon Reports Second Quarter 2012 Results
Aug 1, 2012
|
16.3 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 08/01/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2012. Enzon reported a net loss of $0.7 million, or $0.02 diluted loss per share, for the second quarter of 2012, as compared to a net loss of $7.1 million, or $0.13 diluted loss per share, for...
|
|
Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting
Jul 16, 2012
|
48.1 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 07/16/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of data from pre-clinical studies on the controlled release of human interferon-beta-1b (IFN-β-1b) and an anti-TNF-α antibody fragment (Fab) through releasable PEGylation. The data were presented in a poster sessio...
|
|
Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
Jun 19, 2012
|
9.6 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 06/19/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of results from a Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors. The data were presented in a poster session (Poster #POC02) at the 2012 Advances in Neuroblastoma Re...
|
|
Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting
Jun 4, 2012
|
10.4 KB |
|
| |
PISCATAWAY, NJ -- (MARKETWIRE) -- 06/04/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from the final analysis of a Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast cancer. The data were presented in a poster session (Poster #1017) at the American Society...
|
|
Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China
May 7, 2012
|
11.3 KB |
|
| |
PISCATAWAY, NJ and ZHEJIANG, CHINA -- (Marketwire) -- 05/07/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) and Zhejiang Hisun Pharmaceuticals Co. Ltd (SSE Code: 600267), a leading Chinese pharmaceutical company, announced today a long-term strategic research, development and licensing collaboration. The agreement provides for the research an...
|
|
Enzon Reports First Quarter 2012 Results
May 2, 2012
|
14.3 KB |
|
| |
PISCATAWAY, NJ -- (Marketwire) -- 05/02/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the first quarter of 2012. Enzon reported a net loss of $1.1 million, or $0.02 diluted loss per share, for the first quarter of 2012 as compared to net income of $0.4 million, or $0.01 diluted earnings per share, f...
|
|
Enzon Reports Fourth-Quarter and Full-Year 2011 Results
Mar 12, 2012
|
56.8 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 03/12/12 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth-quarter and full-year 2011. For the three months ended December 31, 2011, Enzon reported a loss from continuing operations of $5.0 million, or $0.10 per diluted share, compared to a loss from continuing...
|
|
Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer
Dec 8, 2011
|
10.2 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 12/08/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from a Phase II, open-label study in which PEG-SN38 (EZN-2208) demonstrated notable activity in patients with previously treated metastatic breast cancer. The data were presented in a poster session (Poster P3-16-18) at the San Antoni...
|
|
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
Nov 12, 2011
|
12.6 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/12/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of clinical and preclinical data from three messenger ribonucleic acid (mRNA) product candidates based on the Company's locked nucleic acid (LNA) technology platform at the AACR-NCI-EORTC International Conference: Molecular...
|
|
Enzon Reports 3rd Quarter 2011 Results
Nov 3, 2011
|
51.6 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/03/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2011. For the third quarter of 2011, Enzon reported a loss from continuing operations of $9.1 million, or $0.19 diluted loss per share, as compared to a loss from continuing operations of $8.4...
|
|
Enzon Announces Management Change, Forms Special Committee of the Board
Oct 17, 2011
|
8.8 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 10/17/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that Ana I. Stancic, C.P.A., M.B.A., current Senior Vice President, Finance and Chief Financial Officer, has been promoted to Chief Operating Officer, Principal Executive Officer and Executive Vice President, effective immediately. She wil...
|
|
Enzon Announces Reduction in Force to Align Operations with Research and Development Activities
Sep 22, 2011
|
7.7 KB |
|
| |
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is
implementing a plan to reduce its workforce and operating costs to more
closely align its resources with the Company's research and development
activities.
The reduction in force will...
|
|
Enzon Reports 2nd Quarter 2011 Results
Aug 4, 2011
|
53.3 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 08/04/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2011. For the second quarter of 2011, Enzon reported a loss from continuing operations of $7.1 million, or $0.13 diluted loss per share, as compared to a loss from continuing operations of $5...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter